Zucara Therapeutics is a leading brand that is revolutionizing the diabetes treatment landscape. Their innovative approach focuses on developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. By targeting and regulating the hormone somatostatin in the pancreas, Zucara's technology offers a clear advantage over existing drug therapies.

While current treatments can only rescue individuals already experiencing dangerous low blood sugar, Zucara's method acts as a preventative measure. With over 422 million people worldwide living with diabetes, Zucara's groundbreaking solution is poised to make a significant impact. By effectively managing hyperglycemia (high blood sugar levels) and mitigating the risk of hypoglycemia, Zucara's therapy not only enhances patient safety but also reduces the incidence of complications such as cardiovascular effects, ultimately improving both patient health and the cost of care.

Founded in 2014 as a spin-out company by TIAP and adMare BioInnovations, Zucara has garnered support from esteemed institutions and organizations such as JDRF International and The Helmsley Charitable Trust. Their dedicated team, including renowned academic founders, has developed strong evidence and compelling technology to restore normal glucagon response and prevent hypoglycemia. Zucara's journey is now in clinical development, with Phase 1 and Phase 2 clinical trials fueled by a US$21M Series A financing led by the Perceptive Xontogeny Venture Fund.

In short, Zucara Therapeutics is at the forefront of diabetes innovation, providing hope and a preventative solution for individuals living with this condition